Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edward Elliott

Foot and Ankle Surgery Decatur, IL Doctor of Podiatric Medicine

NPI 1083957088 CMS profile 2784179

2 Memorial Dr Ste 305, Decatur, IL 62526

Open in the dashboard

General payments

$2,370

32 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edward Elliott of Decatur, IL is reported in the CMS Open Payments database as having received $2,370 across 32 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 23rd percentile of Foot and Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $84 4
2024 General $90 4
2023 General $64 3
2022 General $214 4
2021 General $252 2
2020 General $54 4
2019 General $1,612 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edward Elliott
  • Foot and Ankle Surgery median
  • Middle half of Foot and Ankle Surgery
  • National median

In program year 2025, general payments to Edward Elliott were reported at $84. Among 650 Foot and Ankle Surgery profiles paid that year, the median was $1,183 and the middle half received between $267 and $6,309.

Show as a table
Year Edward Elliott Foot and Ankle Surgery median Middle half National median
2019 $1,612 $1,327 $279–$5,421 $163
2020 $54 $795 $121–$3,473 $114
2021 $252 $1,289 $201–$4,963 $132
2022 $214 $1,539 $270–$6,067 $149
2023 $64 $1,117 $257–$5,264 $160
2024 $90 $1,064 $235–$4,944 $164
2025 $84 $1,183 $267–$6,309 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $1,407 6 payments
  2. Kerecis Limited $246 2 payments
  3. Stryker Corporation $234 4 payments
  4. DePuy Synthes Sales Inc. $203 5 payments
  5. Smith+Nephew, Inc. $118 7 payments
  6. Organogenesis Inc. $72 4 payments
  7. Daiichi Sankyo Inc. $31 1 payment
  8. Treace Medical Concepts, Inc. $22 1 payment
  9. Solventum Corporation $22 1 payment
  10. AbbVie, Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $1,317 3 payments
  2. Food and Beverage $1,053 29 payments
Products named General payments · program years 2019–2025
  1. VA-LCP PLATES & SCREWS $1,485 7 payments
  2. AUGMENT INJECTABLE $174 1 payment
  3. Kerecis Omega3 SurgiClose $168 1 payment
  4. Kerecis Omega3 Marigen Wound Care $168 1 payment
  5. Kerecis Omega3 GraftGuide $168 1 payment
  6. Kerecis Omega3 Marigen Wound Care $168 1 payment
  7. Kerecis Omega3 Marigen Wound Care $168 1 payment
  8. BME NITINOL CONTINUOUS COMPRESSION IMPLANTS $94 3 payments
  9. Kerecis Omega3 Wound $78 1 payment
  10. Kerecis Omega3 Surgibind $78 1 payment
  11. Other $545 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

142

Median for Podiatry: 160

Drug cost

$1,575

Median for Podiatry: $2,368

Branded share of claims

59.9%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gentamicin Sulfate Generic 30 $783
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 34 $244
Ondansetron Odt Ondansetron Brand 31 $218
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 20 $182
Doxycycline Monohydrate Generic 12 $109
Meloxicam Generic 15 $40

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$178,709

Of which drugs: $117,081

Medicare patients

326

Average age 73

Services billed

1,413

208 women, 118 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 51%
Diabetes 35%
Ischemic heart disease 29%
Chronic kidney disease 24%
Depression 23%
Atrial fibrillation 18%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 16 96 $67

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

32 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Foot and Ankle Surgery in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record